Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study

Research output: Contribution to journalJournal articleResearchpeer-review

  • Lasse Folkersen
  • Boel Brynedal
  • Lina Marcela Diaz-Gallo
  • Daniel Ramsköld
  • Klementy Shchetynsky
  • Helga Westerlind
  • Yvonne Sundström
  • Danika Schepis
  • Aase Hensvold
  • Nancy Vivar
  • Maija-Leena Eloranta
  • Lars Rönnblom
  • Brunak, Søren
  • Vivianne Malmström
  • Anca I Catrina
  • Ulrik Gw Mørch
  • Lars Klareskog
  • Leonid Padyukov
  • Louise Berg

OBJECTIVE: In rheumatoid arthritis (RA) several recent efforts have sought to discover means of predicting which patients would benefit from treatment. However, results have been discrepant with few successful replications. Our objective was to build a biobank with DNA, RNA and protein measurements to test the claim that the current state-of-the-art precision medicine will benefit RA patients.

METHODS: We collected 451 blood samples from 61 healthy individuals and 185 RA patients initiating treatment, before treatment initiation and at a 3 month follow-up time. All samples were subjected to high-throughput RNA sequencing, DNA genotyping, extensive proteomics and flow cytometry measurements, as well as comprehensive clinical phenotyping. Literature review identified 2 proteins, 52 single-nucleotide polymorphisms (SNPs) and 72 gene-expression biomarkers that had previously been proposed as predictors of TNF inhibitor response (∆DAS28-CRP).

RESULTS: From these published TNFi biomarkers we found that 2 protein, 2 SNP and 8 mRNA biomarkers could be replicated in the 59 TNF initiating patients. Combining these replicated biomarkers into a single signature we found that we could explain 51% of the variation in ∆DAS28-CRP. This corresponds to a sensitivity of 0.73 and specificity of 0.78 for the prediction of three month ∆DAS28-CRP better than -1.2.

CONCLUSIONS: The COMBINE biobank is currently the largest collection of multi-omics data from RA patients with high potential for discovery and replication. Taking advantage of this we surveyed the current state-of-the-art of drug-response stratification in RA, and identified a small set of previously published biomarkers available in peripheral blood which predicts clinical response to TNF blockade in this independent cohort.

Original languageEnglish
JournalMolecular medicine (Cambridge, Mass.)
Pages (from-to)3223328
Publication statusPublished - 2016
Externally publishedYes

    Research areas

  • Journal Article

ID: 177048389